Not Yet Recruiting
Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab
NCT07720180
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
- Locations
-
- Medical University of South Carolina Hollings Cancer Center Charleston, South Carolina, United States